Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.

Gunma, JP

IMMUNO-BIOLOGICAL LABORATORIES CO., LTD. Patent applications
Patent application numberTitlePublished
20120124681DNA FRAGMENT AND PHARMACEUTICAL COMPOSITION - Provided are a DNA fragment, a pharmaceutical composition, and the like, which can simplify the period of creating knockout animals. The DNA fragment includes: a detection sequence that codes for a detection marker other than drug resistance (preferably a visually-detectable marker); a resistance sequence that codes for a resistance marker for a drug that inhibits the proliferation of one or more species of at least prokaryotic organisms; a promoter sequence that is located upstream of the resistance sequence and functions in prokaryotic organisms; and a regulatory sequence that is located upstream of all of the above sequences and, only when inserted into a target region of the genome of at least one species of eukaryotic organism, induces the expression of a sequence located downstream. The detection sequence and the resistance sequence are arranged so as to be capable of action.05-17-2012
20110312000MONOCLONAL ANTIBODY AND USE THEREOF - The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.12-22-2011
20110129524THERAPEUTIC AGENT FOR CANCER, AND METHOD FOR TREATMENT OF CANCER - [Problems] To provide a technique which enables an effective antibody therapy for cancer which targets for FGFR1 without the need of using any effective antibody having high specificity and a potent cell-killing activity.06-02-2011
20100323375AGENT AND METHOD FOR DIAGNOSIS ON THE OCCURRENCE OF ALZHEIMER'S DISEASE OR THE TENDENCY TO DEVELOP ALZHEIMER'S DISEASE - Disclosed are: an agent, an apparatus and a method for the diagnosis of a disease associated with the abnormality in γ-secretase; a method for providing information for the diagnosis of a disease associated with the abnormality in γ-secretase; a method for monitoring the condition or the degree of progression of a disease associated with the abnormality in γ-secretase; and a method for determining the therapeutic effect of a therapeutic agent on a disease associated with the abnormality in γ-secretase. More specifically disclosed are: a diagnostic agent for a disease associated with the abnormality in γ-secretase, which comprises an antibody capable of recognizing a digestion product of an alcadein with α-secretase or γ-secretase or a fragment of the antibody; and others.12-23-2010
20100111939MONOCLONAL ANTIBODY AND USE THEREOF - The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.05-06-2010

Patent applications by IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.